KindredBio Appoints Kevin Schultz, Former CSO of Merial, as CSO

Dr. Schultz, former Chief Scientific Officer and Global Head of R&D for Merial, joins the KindredBio team.

SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has appointed Kevin Schultz, DVM, PhD, former Chief Scientific Officer and Head of R&D for Merial, as Chief Scientific Officer and Head of R&D for KindredBio.

Read more

KindredBio Announces Protocol Concurrences from the FDA on Pivotal Studies

FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies.

SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) field studies for KIND-001 and KIND-002. A protocol concurrence, similar to a Special Protocol Assessment for a human study, is a written commitment from the FDA that it is in agreement with the design, execution, and the analysis proposed in the protocol.

Read more